Literature DB >> 33321173

Role of gut microbiota in epigenetic regulation of colorectal Cancer.

Yinghui Zhao1, Chuanxin Wang2, Ajay Goel3.   

Abstract

Colorectal cancer (CRC) remains one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths worldwide. The stepwise accumulation of epigenetic alterations in the normal colorectal epithelium has been reported to act as a driving force for the initiation and promotion of tumorigenesis in CRC. From a mechanistic standpoint, emerging evidence indicates that within the colorectal epithelium, the diverse gut microbiota can interact with host cells to regulate multiple physiological processes. In fact, recent studies have found that the gut microbiota represents a potential cause of carcinogenesis, invasion, and metastasis via DNA methylation, histone modifications, and non-coding RNAs - providing an epigenetic perspective for the connection between the gut microbiota and CRC. Herein, we comprehensively review the recent research that provides a comprehensive yet succinct evidence connecting the gut microbiota to CRC at an epigenetic level, including carcinogenic mechanisms of cancer-related microbiota, and the potential for utilizing the gut microbiota as CRC biomarkers. These scientific findings highlight a promising future for manipulating the gut microbiota to improve clinical outcomes in patients suffering from CRC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Diagnostic biomarkers; Epigenetic modifications; Gut microbiota; Non-coding RNAs

Mesh:

Year:  2020        PMID: 33321173      PMCID: PMC7856101          DOI: 10.1016/j.bbcan.2020.188490

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  163 in total

1.  Peutz-Jeghers Syndrome.

Authors:  Shreya Sengupta; Sayantan Bose
Journal:  N Engl J Med       Date:  2019-01-31       Impact factor: 91.245

2.  Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.

Authors:  Mara Roxana Rubinstein; Jung Eun Baik; Stephen M Lagana; Richard P Han; William J Raab; Debashis Sahoo; Piero Dalerba; Timothy C Wang; Yiping W Han
Journal:  EMBO Rep       Date:  2019-03-04       Impact factor: 8.807

3.  Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer.

Authors:  Qiaoyi Liang; Jonathan Chiu; Yingxuan Chen; Yanqin Huang; Akira Higashimori; Jingyuan Fang; Hassan Brim; Hassan Ashktorab; Siew Chien Ng; Simon Siu Man Ng; Shu Zheng; Francis Ka Leung Chan; Joseph Jao Yiu Sung; Jun Yu
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

4.  Folate production by bifidobacteria as a potential probiotic property.

Authors:  Anna Pompei; Lisa Cordisco; Alberto Amaretti; Simona Zanoni; Diego Matteuzzi; Maddalena Rossi
Journal:  Appl Environ Microbiol       Date:  2006-10-27       Impact factor: 4.792

Review 5.  Experimental and analytical tools for studying the human microbiome.

Authors:  Justin Kuczynski; Christian L Lauber; William A Walters; Laura Wegener Parfrey; José C Clemente; Dirk Gevers; Rob Knight
Journal:  Nat Rev Genet       Date:  2011-12-16       Impact factor: 53.242

6.  Fusobacterium nucleatum Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations.

Authors:  Minoru Koi; Yoshiki Okita; John M Carethers
Journal:  J Anus Rectum Colon       Date:  2018-04-25

7.  Elimination of protein aggregates prevents premature senescence in human trisomy 21 fibroblasts.

Authors:  Nobutoshi Nawa; Katsuya Hirata; Keiji Kawatani; Toshihiko Nambara; Sayaka Omori; Kimihiko Banno; Chikara Kokubu; Junji Takeda; Ken Nishimura; Manami Ohtaka; Mahito Nakanishi; Daisuke Okuzaki; Hidetoshi Taniguchi; Hitomi Arahori; Kazuko Wada; Yasuji Kitabatake; Keiichi Ozono
Journal:  PLoS One       Date:  2019-07-29       Impact factor: 3.240

8.  Microbiota Profile and Impact of Fusobacterium nucleatum in Colorectal Cancer Patients of Barretos Cancer Hospital.

Authors:  Ana Carolina de Carvalho; Leandro de Mattos Pereira; José Guilherme Datorre; Wellington Dos Santos; Gustavo Noriz Berardinelli; Marcus de Medeiros Matsushita; Marco Antonio Oliveira; Ronilson Oliveira Durães; Denise Peixoto Guimarães; Rui Manuel Reis
Journal:  Front Oncol       Date:  2019-08-29       Impact factor: 6.244

Review 9.  Microbiota in the Gastrointestinal Tract.

Authors:  Walburga Dieterich; Monic Schink; Yurdagül Zopf
Journal:  Med Sci (Basel)       Date:  2018-12-14

10.  High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution.

Authors:  Benjamin J Callahan; Joan Wong; Cheryl Heiner; Steve Oh; Casey M Theriot; Ajay S Gulati; Sarah K McGill; Michael K Dougherty
Journal:  Nucleic Acids Res       Date:  2019-10-10       Impact factor: 16.971

View more
  5 in total

Review 1.  Role of gene regulation and inter species interaction as a key factor in gut microbiota adaptation.

Authors:  Shuang Gao; Muhammad Imran Khan; Fadia Kalsoom; Zhen Liu; Yanxin Chen; Zhengli Chen
Journal:  Arch Microbiol       Date:  2022-05-20       Impact factor: 2.552

Review 2.  Biomarkers to Detect Early-Stage Colorectal Cancer.

Authors:  Jacqueline I Keenan; Frank A Frizelle
Journal:  Biomedicines       Date:  2022-01-25

Review 3.  Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy.

Authors:  Monika Kvakova; Anna Kamlarova; Jana Stofilova; Veronika Benetinova; Izabela Bertkova
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

4.  The difference of gut microbiome in different biliary diseases in infant before operation and the changes after operation.

Authors:  Xinhe Sun; Yaoyao Cai; Wenwen Dai; Weiwei Jiang; Weibing Tang
Journal:  BMC Pediatr       Date:  2022-08-24       Impact factor: 2.567

5.  Explore and Analyze the Composition and Characteristics of Intestinal Microbiota between Gastric Cancer Patients and Healthy People.

Authors:  Fang He; Fang Wang; Jiali Yang; Shaoqi Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-08       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.